Is there a light at the end of the tunnel? It certainly appears to be, especially for a few key areas, including artificial intelligence, sustainability and clean tech, health tech and digital health solutions, among others.
We know there has been an ongoing slowdown in venture capital funding for startups – this has been the case since 2022 and it continues to impact startups at all stages of growth. The slowdown appears to be leveling from 2022, however, suggesting that the market may be normalizing. Furthermore, investors are still active in certain key sectors and notable trends are beginning to emerge in the landscape this year
View referenced article
Related Insights
October 7, 2026
Foley Career Perspectives
Different Strengths, One Team: An Interview With Texas Attorneys of the Year Chris Converse and Chris Babcock
The firm’s collaborative culture was on full display when partners Chris Converse and Chris Babcock worked together on a “rare kind of legal achievement” that required both strategic vision and deep technical analysis.
October 7, 2026
Foley Viewpoints
What Your Software Company Is Worth Now
Rob Bartlett of Jefferies joined the panel I moderated last month on whether companies should buy, sell, or wait. This week I read his team’s monthly software valuation update, with data through September 30. I read a lot of bank decks. This one I read twice.
October 7, 2026
Foley Viewpoints
Beyond Animal Testing: FDA's 2026 Framework for Fit-for-Purpose NAMs
In September 2026, FDA took another significant step toward integrating new approach methodologies, or NAMs, into drug development by issuing a Direct Final Rule on Nonclinical Testing Terminology (the “September 2026 direct final rule”).[